With regard to IL-6 and GM-CSF
, the main source seems to be fibroblasts, but results were too variable to conclude whether cocultures with or without silica enhance the mRNA levels.
Results suggest that post-vaccination GM-CSF
producing T-cells induce clinically significant anti-tumor effects which could slow tumor growth and improve survival.
Then, they peripherally injected GM-CSF
into two groups of mice - those genetically altered to develop memory problems mimicking Alzheimer's disease and normal, aged mice.
How much and when GM-CSF
should be given after a radiation accident remains unclear, Gale says.
This indicates that GM-CSF
is a key mediator in smoke-induced lung inflammation and its neutralization may have therapeutic implications in diseases such as COPD.
the researchers used a retrovirus to transfer an extra GM-CSF
gene into male and female mice and examined the mouse progeny for effects of increased production of the cell growth factor.
KB003 is an anti-GM-CSF
mAb that KaloBios intends to evaluate in oncology indications where GM-CSF
may play a key role, such as chronic myelomonocytic leukemia (CMML).
It is the only product in clinical development that combines an oncolytic effect while inducing tumour cells to secrete GM-CSF
, a powerful immune stimulator, potentially enhancing the destruction of metastatic tumour deposits.
In the recent study, the authors report that intravenous infusion with GM-CSF
for two weeks produced significant increases in white cells called neutrophils, monocytes and eosinophils.
OPTiM Study Design and Results Study 005/05, referred to as OPTiM, was a Phase 3, multicenter, open-label, randomized clinical trial comparing talimogene laherparepvec to GM-CSF
in patients with advanced melanoma (stage IIIB, IIIC, or IV) that was not surgically resectable.
is a first in class oncolytic vaccine.
The abstract entitled 'Correlation of robust local reactions prompting GM-CSF
dose reduction to clinical response in a Phase II trial of the AE37+GM-CSF
HER2 peptide vaccine' by Julia Greene, et al was presented at the Clinical Trials in Progress session of the AACR on April 20.
Pexa-Vec was also engineered to express GM-CSF
, a white blood cell growth factor leading to the activation of a systemic immune response to kill tumor cells throughout the body.
can cross the blood brain barrier to access tumours in the brains of humans and preclinical research examining the synergies associated with treatment in animal models with GM-CSF
prior to administering REOLYSIN[sup.
Serious adverse events occurred in 26 percent of talimogene laherparepvec patients and 13 percent of GM-CSF